Gamis AS, Alonzo TA, Meshinchi S, Sung L, Gerbing RB, Raimondi SC, et al. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531. J Clin Oncol. 2014;32:3021–32.
Google Scholar
Lambert J, Pautas C, Terre C, Raffoux E, Turlure P, Caillot D, et al. Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial. Haematologica. 2019;104:113–9.
Google Scholar
Hills RK, Castaigne S, Appelbaum FR, Delaunay J, Petersdorf S, Othus M, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol. 2014;15:986–96.
Google Scholar
Lamba JK, Chauhan L, Shin M, Loken MR, Pollard JA, Wang YC, et al. CD33 splicing polymorphism determines gemtuzumab ozogamicin response in De Novo acute myeloid leukemia: report from randomized phase III Children’s Oncology Group trial AAML0531. J Clin Oncol. 2017;35:2674–82.
Google Scholar
Chauhan L, Shin M, Wang Y-C, Loken M, Pollard J, Aplenc R, et al. CD33_PGx6_Score predicts gemtuzumab ozogamicin response in childhood acute myeloid leukemia: a report from the Children’s Oncology Group. JCO Precis Oncol. 2019;3:PO.18.00387.
Google Scholar
Papageorgiou I, Loken MR, Brodersen LE, Gbadamosi M, Uy GL, Meshinchi S, et al. CCGG deletion (rs201074739) in CD33 results in premature termination codon and complete loss of CD33 expression: another key variant with potential impact on response to CD33-directed agents. Leuk Lymphoma. 2019;60:2287–90.
Google Scholar
Smukowski Heil C. Loss of heterozygosity and its importance in evolution. J Mol Evol. 2023;91:369–77.
Google Scholar
Dutta A, Schacherer J. The dynamics of loss of heterozygosity events in genomes. EMBO Rep. 2025;26:602–12.
Google Scholar
Laubli H, Nalle SC, Maslyar D. Targeting the Siglec-Sialic acid immune axis in cancer: current and future approaches. Cancer Immunol Res. 2022;10:1423–32.
Google Scholar
Graus F, Sabater L, Gaig C, Gelpi E, Iranzo A, Dalmau JO, et al. Anti-IgLON5 disease 10 years later: what we know and what we do not know. Neurol Neuroimmunol Neuroinflamm. 2025;12:e200353.
Google Scholar
Kumar Y, Yang J, Hu T, Chen L, Xu Z, Xu L, et al. Massive interstitial copy-neutral loss-of-heterozygosity as evidence for cancer being a disease of the DNA-damage response. BMC Med Genomics. 2015;8:42.
Google Scholar
Bicher A, Ault K, Kimmelman A, Gershenson D, Reed E, Liang B. Loss of heterozygosity in human ovarian cancer on chromosome 19q. Gynecol Oncol. 1997;66:36–40.
Google Scholar
Nakamura M, Yang F, Fujisawa H, Yonekawa Y, Kleihues P, Ohgaki H. Loss of heterozygosity on chromosome 19 in secondary glioblastomas. J Neuropathol Exp Neurol. 2000;59:539–43.
Google Scholar
Mora J, Cheung NK, Chen L, Qin J, Gerald W. Loss of heterozygosity at 19q13.3 is associated with locally aggressive neuroblastoma. Clin Cancer Res. 2001;7:1358–61.
Google Scholar
Gronseth CM, McElhone SE, Storer BE, Kroeger KA, Sandhu V, Fero ML, et al. Prognostic significance of acquired copy-neutral loss of heterozygosity in acute myeloid leukemia. Cancer. 2015;121:2900–8.
Google Scholar
